Johnson & Johnson (JNJ) Depreciation & Amortization (CF) (2009 - 2026)
Johnson & Johnson (JNJ) posted Depreciation & Amortization (CF) of $2.0 billion for Q1 2026, little changed sequentially from $2.0 billion in Q4 2025, and up 13.09% YoY from $1.8 billion in Q1 2025.
Johnson & Johnson (JNJ) Depreciation & Amortization (CF) (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Depreciation & Amortization (CF) data on file, last reported at $2.0 billion in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 13.09% year-over-year to $2.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.7 billion (up 6.02% YoY) and the FY2025 annual result came in at $7.5 billion, up 2.23% from the prior year.
- Depreciation & Amortization (CF) held at $2.0 billion in Q1 2026 per JNJ's latest filing, from $2.0 billion in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $2.0 billion in Q4 2025, with the low at $1.4 billion in Q1 2023.
- Average Depreciation & Amortization (CF) over 5 years is $1.8 billion, with a median of $1.8 billion recorded in 2023.
- Year-over-year, Depreciation & Amortization (CF) increased 29.52% in 2023 and dropped 7.86% in 2024.
- Johnson & Johnson's Depreciation & Amortization (CF) stood at $1.8 billion in 2022, then climbed by 4.18% to $1.8 billion in 2023, then gained by 2.88% to $1.9 billion in 2024, then advanced by 6.07% to $2.0 billion in 2025, then decreased by 0.35% to $2.0 billion in 2026.
- Business Quant data shows JNJ's Depreciation & Amortization (CF) at $2.0 billion in Q1 2026, $2.0 billion in Q4 2025, and $1.8 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Amort. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 509.00 Mn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 2.00 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 188.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 1.37 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 581.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 1.12 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 93.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 1.61 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 204.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 2.00 Bn |
| Mar 29, 2026 | 2.00 Bn |
| Dec 28, 2025 | 2.01 Bn |
| Dec 28, 2025 | 2.01 Bn |
| Sep 28, 2025 | 1.78 Bn |
| Sep 28, 2025 | 1.78 Bn |
| Jun 29, 2025 | 1.94 Bn |
| Jun 29, 2025 | 1.94 Bn |
| Mar 30, 2025 | 1.77 Bn |
| Mar 30, 2025 | 1.77 Bn |
| Dec 29, 2024 | 1.90 Bn |
| Dec 29, 2024 | 1.90 Bn |
| Sep 29, 2024 | 1.85 Bn |
| Sep 29, 2024 | 1.85 Bn |
| Jun 30, 2024 | 1.78 Bn |
| Jun 30, 2024 | 1.78 Bn |
| Mar 31, 2024 | 1.82 Bn |
| Mar 31, 2024 | 1.82 Bn |
| Dec 31, 2023 | 1.84 Bn |
| Dec 31, 2023 | 1.84 Bn |